GEN Exclusives

More »

GEN News Highlights

More »
Jun 18, 2007

Bachem Acquires Merck Biosciences’ Business Unit Clinalfa

  • Bachem has acquired the business unit of Merck Biosciences that operates under the brand of Clinalfa®. The transaction includes Clinalfa’s existing customer base, the team headed by Hana Märki, and technical know-how on the Clinalfa products.

    Clinalfa offers a wide range of biologically active peptides and other biologically active products for use in clinical research at scientific institutions and universities across the world. Bachem reports that Clinalfa will substantially expand its range of finished dosage forms for clinical trials and will enable the company to broaden its customer base in this business area, expanding it beyond the existing main target group of biotechnology companies.

    “We are pleased that this acquisition of the Clinalfa® brand enables us to strengthen our range of services in the field of research and to win additional customers, primarily in the university sector and customers who work with so-called challenging agents,” says Walter Isler, head of marketing/sales at Bachem. “This puts us in an even better position to realize our ambition of providing comprehensive support for the clinical development of peptide-based and other biologically active substances with quality products and services.”


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »